The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.
* Co and zs pharma are evaluating content of CRL and will work closely with FDA to determine appropriate next steps for NDA * CRL refers to observations arising from a pre-approval manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback